The Street Medicine Auto-Refraction Technology (SMART) Study: A Model for Screening and Treating Refractive Error in Persons Experiencing Homelessness

Retinal Diseases

Screening for retinopathy of prematurity in China: a five-year cohort study in seven screening centers

BMC Ophthalmol

Zhong Y, Lin X, Yang Y, He L, Li N, Lu J, Zhou Y, Zhang R, Wang Y, Zhang Z, Yang M, Yin H, Zhao M, Li X, Liang J, Cheng Y

doi: 10.1186/s12886-024-03836-5

RECOMMENDED

Retinal Diseases

Refractive Error in Inherited Retinal Disease

★ 3 Recommended by Prof. Dr Ke Yao, Faculty Member

Am J Ophthalmol

Yassin SH, Wagner NE, Khuu T, Schmidt R, Igelman AD, Marra M, Schwartz H, Walker E, Nagiel A, Yang P, Everett LA, Pennesi ME, Borooah S

doi: 10.1016/j.ajo.2024.09.011

Macular Diseases

Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice

Ophthalmol Ther

Debourdeau E, Beylerian H, Nguyen V, Barthelmes D, Gillies M, Gabrielle PH, Vujosevic S, Otoole L, Puzo M, Creuzot-Garcher C, Wolff B, Daien V, Fight Retinal Blindness! Study Group

doi: 10.1007/s40123-024-00983-2

Further Publications

Establishment of Myopia Occurrence Prediction Model in Non-myopic Children Using Cycloplegic Refraction and Prior Axial Length Change

Ophthalmology

Xu S, Ruan Z, Wang Y, Jiang J, Zhao F, Tang X, Li C, Guo L, Hu Y, Lu C, Yang X

doi: 10.1016/j.ophtha.2025.06.010

Retinal Diseases

Fundus Refraction Offset as a Personalized Biomarker for 12-Year Risk of Retinal Detachment

Invest Ophthalmol Vis Sci

Yii F, MacCormick IJC, Strang N, Bernabeu MO, MacGillivray T

doi: 10.1167/iovs.66.9.1

Lenses

Prediction of refraction error after toric lens implantation with biometric input data uncertainties and power labelling tolerances

Clin Exp Ophthalmol

Langenbucher A, Szentmáry N, Cayless A, Cooke D, Hoffmann P, Wendelstein J

doi: 10.1111/ceo.14449

Blindness and Vision ImpairmentGlaucoma and Ocular Pressure

Semi-automated screening reveals patients with glaucoma-induced blindness missing out on social support: a cross-sectional study of certificate of visual impairment allocation

Br J Ophthalmol

Thirunavukarasu AJ, Jain N, Yu HCY, Nishimura G, Tandon A, Butt H, Sanghera R, Bourne RRA, Cambridge Students Glaucoma Initiative

doi: 10.1136/bjo-2024-326745

Macular DiseasesFurther Publications

Artificial Intelligence-Based Disease Activity Monitoring to Personalized Neovascular Age-Related Macular Degeneration Treatment: A Feasibility Study

Ophthalmol Sci

Mulyukov Z, Keane PA, Sahni J, Liakopoulos S, Hatz K, Wei Ting DS, Gallego-Pinazo R, Aslam T, Gemmy Cheung CM, De Salvo G, Semoun O, Somfai GM, Stahl A, Lujan BJ, Lorand D

doi: 10.1016/j.xops.2024.100565

Macular Diseases

TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration

Ophthalmol Retina

Regillo C, Kaiser PK, Kertes PJ, Gillies M, Maio-Twofoot T, D'Souza D, Guenther S, Lawrence D, Holz FG

doi: 10.1016/j.oret.2025.05.030

Related content

Screening for retinopathy of prematurity in China: a five-year cohort study in seven screening centers

Refractive Error in Inherited Retinal Disease

Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice

Establishment of Myopia Occurrence Prediction Model in Non-myopic Children Using Cycloplegic Refraction and Prior Axial Length Change

Fundus Refraction Offset as a Personalized Biomarker for 12-Year Risk of Retinal Detachment

Prediction of refraction error after toric lens implantation with biometric input data uncertainties and power labelling tolerances

Semi-automated screening reveals patients with glaucoma-induced blindness missing out on social support: a cross-sectional study of certificate of visual impairment allocation

Artificial Intelligence-Based Disease Activity Monitoring to Personalized Neovascular Age-Related Macular Degeneration Treatment: A Feasibility Study

TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration